This inventor holds 43 USPTO granted patents, plus 2 CIPO patents and 2 EPO patents, primarily in Oligonucleotide Derivatives. Top assignees: Hoechst Aktiengesellschaft, Aventis Pharma Deutschland, Gmbh, Genentech, Inc.. Active years: 1993-2008.
Location History:
- Brookline, MA (US) (1993)
- Kelkheim/Taunus, DE (1997)
- Kelkheim(Taunus), DE (1997)
- Kelkheim, DE (1994 - 2008)
Company Filing History:
21 out of 6,705 
7 out of 330 
5 out of 3,294 
Years Active: 1993-2008
Areas of Expertise:
Title: Anuschirwan Peyman: Innovator in Pharmacological Compounds
Introduction: Anuschirwan Peyman is a noted inventor based in Kelkheim, Germany, with an impressive portfolio of 43 patents to his name. His contributions to the field of pharmacology highlight the importance of innovative compounds in addressing critical health issues.
Latest Patents: Among his latest patents are two significant inventions focused on novel compounds with potential therapeutic applications. The first patent details "Guanidine and amidine derivatives as factor Xa inhibitors," which outlines compounds designed to exhibit a strong antithrombotic effect. These compounds serve as reversible inhibitors of blood clotting enzymes, specifically factor Xa and factor VIIa, and offer therapeutic options for cardiovascular disorders such as thromboembolic diseases and restenoses. Furthermore, the invention includes processes for synthesizing these compounds and their applications within pharmaceutical preparations.
The second patent, titled "Guanidino derivatives as inhibitors of cell adhesion," focuses on acylguanidino derivatives that act as vitronectin receptor antagonists. These compounds are valuable for preventing bone resorption by osteoclasts and have applications in treating conditions related to cell adhesion, including osteoporosis and undesired angiogenesis.
Career Highlights: Throughout his career, Anuschirwan Peyman has demonstrated a commitment to advancing medical science through his innovative inventions. His work at Hoechst Aktiengesellschaft highlights his involvement in leading pharmaceutical projects and research endeavors that have a tangible impact on healthcare.
Collaborations: Peyman has collaborated with notable professionals in the field, including Eugen Uhlmann and Jochen Knolle. These partnerships have facilitated the development of his patents and further enriched his contributions to the pharmaceutical industry.
Conclusion: Anuschirwan Peyman's contributions to innovation in pharmacology and his substantial number of patents underscore his role as a vital inventor in the medical field. His work not only advances the understanding of important pharmacological interactions but also opens the door for new therapies that can significantly aid in the treatment of various diseases.